What set the move off
Investors came into the quarter expecting three major clinical updates from Genmab, and all three broke in the company's favor. Momentum kicked off late Friday after Europe's markets closed, when Genmab reported that Rina-S trimmed the odds of disease getting worse or patients dying by 71 percent in a study group with a type of ovarian cancer.
A few days later, Genmab reported that petosemtamab - now being evaluated for head and neck cancer - halved the risk of death. Those back to back readouts propelled the shares to their steepest weekly climb since 2008, up 44 percent, and pushed the stock to record levels. The move tacked on more than $10 billion in market cap and stretched gains this year to almost 90 percent.
Why analysts are paying attention
Jefferies analyst Benjamin Jackson put it plainly: "Biotechs tend to have this curse that if you develop one really good drug and you make a lot of money from it, finding the next innovation can be challenging," he said. "Genmab is one of those few cases where you can start to say: this has happened."
The company is working to shift from collecting royalties to building products it controls. Royalties from its blood cancer therapy Darzalex are seen slipping as the decade winds down, so the need for new growth engines is real. Owning the commercial rights to petosemtamab means Genmab would capture more of any success versus a royalty stream. As Jackson noted, the firm now has three programs that are not merely royalty plays, but products it plans to launch and advance itself.
Genmab's run also spotlights Denmark's clout in pharma. Roughly one fifth of the country's goods exports come from the life sciences sector. A significant share of that recent momentum stems from Novo Nordisk's weight-loss therapies, and as Novo works to keep pace with Eli Lilly, investors are widening their attention to include Genmab as well.
Breakthrough news can remind investors that fresh tools help refine decision making. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
Targets, sales potential and a note of caution
Analysts rushed to update their models. Van Lanschot Kempen raised the valuation goal to 4,900 Danish kroner, the top figure among Bloomberg-followed analysts and one that suggests nearly 30 percent additional upside from current levels. "Petosemtamab is now firmly on track to become a multi-billion franchise," wrote Kempen's team led by Romy O'Connor, calling it a likely next standard of care.
JPMorgan's team estimates petosemtamab could reach about $5 billion at peak, with $3.5 billion linked to head and neck cancer and the remainder attributed to colorectal disease, per an Oct. 27 note.
Not everyone is chasing the stock. Jyske Bank and AL Sydbank both downgraded shares on Thursday. Sydbank's Søren Løntoft Hansen said the stock could be headed into a quieter stretch as investors await commercial proof points. Jyske Bank's Henrik Hallengreen Laustsen cut the rating to sell, expecting thinner news flow ahead, while acknowledging the latest data "significantly reduce the risk in the pipeline and strengthen the growth profile after Darzalex."
The bottom line for investors
Genmab, established in Copenhagen in 1999 and listed locally the year after, just showed how fast clinical wins can reset valuation, sentiment, and sell side models. The company's tilt toward owning its next wave of products raises the stakes, but also the potential payoff, if petosemtamab and Rina-S deliver in the market.
Smart investors look for steady ways to gain an informative edge over time. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
